Top Markets
Coin of the day
Epigenomics AG Epigenomics AG

Epigenomics AG

ECX
Rangering i aksjer #38936
Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a... Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a molecular diagnostics company dedicated to the early detection of cancer through liquid biopsy methods. Its primary offering, Epi proColon, is a blood-based assay specifically developed for the early identification of colorectal cancer, distributed across the United States, Europe, and China. The company's portfolio further encompasses a blood test for hepatocellular carcinoma and Epi BiSKit, a pre-analytical solution providing reagents essential for preparing bisulfite-converted DNA. Epigenomics' research and development initiatives are focused on pinpointing relevant biomarkers in human tissue and subsequently creating and securing patents for associated in vitro diagnostic blood tests.
Aksjekurs
$0.83030862
Sist synkronisert: 2024-06-27
Markedsverdi
$726.64K
Endring (1 dag)
-1.35%
Endring (1 år)
0.00%
Land
DE
Handel Epigenomics AG (ECX)

Kategori

P/B-forhold for Epigenomics AG (ECX)
P/B-forhold per 2026 TTM: 0
Ifølge Epigenomics AG sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Epigenomics AG fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
4.0441 -
US
2.6166 -
US
- -
CN
28.7765 -
US
21.3575 -
US